Take­da winds down Ther­a­vance pact, culls part­nered Crohn's pro­gram af­ter PhII flops

Take­da re­vealed in its lat­est quar­ter fil­ing that it’s end­ing a sev­en-year al­liance with Ther­a­vance as the com­pa­nies fold a pro­gram that flopped in Phase IIb, while al­so giv­ing the axe to a sec­ond part­ner­ship with France’s En­terome in Crohn’s. These pro­grams were among sev­en tri­als Take­da is cut­ting for var­i­ous can­cers and oth­er dis­eases amidst a plan to lay off more than 180 work­ers.

TAK-954, a can­di­date be­ing de­vel­oped in Phase II tri­als for pa­tients be­fore surgery to see if it could en­hance the re­cov­ery of gas­troin­testi­nal func­tion af­ter surgery to re­sec­tion the small or large in­tes­tine, was al­so cut. Some pa­tients al­so got the drug post-surgery to see if it helped at all in the tri­al. Take­da not­ed in its quar­ter­ly re­port that the Phase IIb study for TAK-954 did not meet its end­points.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.